Advances in Multimodal AI: de-risking drug development from discovery to CDx

On 3 November, translational and precision medicine leaders from Amgen, Regeneron, Modella AI (a member of the AstraZeneca group), and Waiv will assess where AI-powered digital pathology and multimodal approaches are de-risking drug development today, from early discovery through to companion diagnostics.

As antibody-drug conjugates and bispecifics push biomarker strategy past target expression at the cell surface, success increasingly depends on signals from the tumor microenvironment, spatial biology, and cancer cell morphology that conventional pathology struggles to quantify.

The panel will examine where AI digital pathology and multimodal models are already delivering measurable value across stratification, biomarker discovery, and response monitoring, and where they are still developing, along with the bar translational teams set before trusting an AI-derived biomarker and what it takes to move from a working model to a clinically deployable, regulatory-grade test.